As Ibr‐7 was capable of overcoming the Mcl‐1 caused by ABT‐199 mono‐treatment, it was assumed that Ibr‐7 would sensitize NSCLC cells to ABT‐199. The gene discussed is MCL1; the disease is non-small cell lung carcinoma.